Dr. Paula Raffin Pohlmann, MD, PhD, MSC

Dr. Paula Raffin Pohlmann, MD, PhD, MSC

Languages: Portuguese, English
Fax: (202) 444-2886

Contact this Provider:

  • Hematology
  • Medical Oncology
Conditions I Treat
  • breast cancer
  • cancer
  • microcalcifications
Procedures I Perform
  • mammogram
About the Provider

Paula R. Pohlmann, MD, PhD, is a board-certified medical oncologist with more than 20 years of experience in cancer treatment and research. In her clinic at the Lombardi Comprehensive Cancer Center, Dr. Pohlmann treats patients with breast cancer, and also conducts phase I, II and III clinical trials involving any malignancy, in particular breast, gastrointestinal and gynecologic.
The recipient of many grants focused on breast cancer, gynecological cancer, molecular targets and immunotherapy, Dr. Pohlmann has published extensively. She currently leads several clinical trials developing new diagnostic biomarkers and therapies.
Dr. Pohlmann's Philosophy of Care
I work methodically to provide each patient with exceptional cancer care and treatment. To start, I review all previous treatment with my patients. I seek to understand my patients' expectations and wishes and then discuss available therapies with them, including innovative treatments and alternatives. These discussions help me develop a personalized treatment plan based on cutting edge scientific evidence that may offer solutions for each patient's condition.
My work aims to return every person with cancer back to a normal, healthy life quickly, by providing the most advanced, professional, sensitive and compassionate patient care available.

  • Residency Program: Vanderbilt University Medical Center (2011)
  • Fellowship Program: Vanderbilt University (2009)
  • Fellowship Program: Vanderbilt University Medical Center (2009)
  • Fellowship Program: Hospital de Clinicas (1997)
  • Residency Program: Hospital de Clinicas (1994)
  • Medical School: Universidade Federal do Rio Grande do Sul (1992)
  • Board Certification: American Board of Internal Medicine, Internal Medicine

  • Podium and poster presentation: Tumor profiling of 1168 geriatric breast tumors, ASCO Breast Symposium, September 2015. San Francisco, California.
  • Principal Investigator, Novel Diagnostic to Predict Patient Responsiveness to Trastuzumab for testing of NSABP B-41 clinical trial samples. October 2015. Washington, DC.
  • Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). Abstract Temporary ID#169304. 2016 ASCO Annual Meeting. Chicago, Illinois.
  • Co-editor, "Frontiers in Women's Cancers" section, Frontiers in Oncology, Lausanne Switzerland.
  • A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis. J Clin Oncol 33, 2015 (suppl 3; abstr TPS494). 2015 Gastrointestinal Cancers Symposium, San Francisco, California (abstract).

Practice Locations
  • 3800 Reservoir Road Northwest
    Washington, DC 20007
    View Map

    Accepting New Patients
Member of Medical Staff
  • MedStar Georgetown University Hospital
  • Career Development Award. Kalf Research Fellowship in translational research, Amsterdam, Netherlands
  • Most Outstanding Fellw Award. Clinical Fellow at Division of Hematology-Oncology, Vanderbilt University, Nashville, Tennessee
  • People's Choice Winner for Life Sciences/Health Care Track. Governor's Innovation Conference with technology:
  • Teacher of the Year: Hematology-Oncology Fellows, Division of Hematology and Oncology, MedStar Georgetown University Hospital. Washington, DC
  • Shining Star Award. Clinical Fellow at Division of Hematology-Oncology, Vanderbilt University, Nashville, Tennessee